Compare NEGG & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEGG | XBIT |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 66.8M |
| IPO Year | N/A | 2015 |
| Metric | NEGG | XBIT |
|---|---|---|
| Price | $12.70 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.6K | 36.5K |
| Earning Date | 08-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.50 | $2.09 |
| 52 Week High | $96.29 | $3.44 |
| Indicator | NEGG | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 47.52 |
| Support Level | $12.52 | $2.16 |
| Resistance Level | $14.98 | $2.48 |
| Average True Range (ATR) | 0.71 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 14.44 | 66.67 |
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.